肝移植后肝细胞癌复发预测的分子线索
Molecular Clues for Prediction of Hepatocellular Carcinoma Recurrence After Liver Transplantation.
作者信息
Badwei Nourhan
机构信息
Tropical Medicine, Gastroenterology and Hepatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
出版信息
J Clin Exp Hepatol. 2023 Sep-Oct;13(5):804-812. doi: 10.1016/j.jceh.2023.02.006. Epub 2023 Feb 22.
Abstract
Recurrence after liver transplantation (LT) for hepatocellular carcinoma (HCC) is one of the commonest causes of cancer-related mortality. Thus, advances in the HCC molecular features have paid researchers great attention to identifying the different risk factors that could aid in liver cancer initiation and progression for earlier prediction of post-operative HCC recurrence risk. Our review has focused on the possible molecular onco-drivers' for HCC recurrence post-LT that may represent diagnostic/prognostic tools and scoring models for the proper selection of LT candidates with HCC.
摘要
肝细胞癌（HCC）肝移植（LT）后的复发是癌症相关死亡的最常见原因之一。因此，HCC分子特征的进展使研究人员高度关注识别不同的风险因素，这些因素有助于肝癌的发生和发展，以便更早地预测术后HCC复发风险。我们的综述重点关注LT后HCC复发可能的分子肿瘤驱动因素，这些因素可能代表诊断/预后工具以及评分模型，用于正确选择HCC的LT候选者。
相似文献
1
Molecular Clues for Prediction of Hepatocellular Carcinoma Recurrence After Liver Transplantation.肝移植后肝细胞癌复发预测的分子线索
J Clin Exp Hepatol. 2023 Sep-Oct;13(5):804-812. doi: 10.1016/j.jceh.2023.02.006. Epub 2023 Feb 22.
2
Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma.高危复发性肝细胞癌的预防性肝移植
World J Hepatol. 2016 Nov 8;8(31):1309-1317. doi: 10.4254/wjh.v8.i31.1309.
3
R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation.R3-AFP评分是一种新的综合工具，用于优化肝移植后肝细胞癌复发的预测。
JHEP Rep. 2022 Feb 2;4(5):100445. doi: 10.1016/j.jhepr.2022.100445. eCollection 2022 May.
4
Development and validation of a REcurrent Liver cAncer Prediction ScorE (RELAPSE) following liver transplantation in patients with hepatocellular carcinoma: Analysis of the US Multicenter HCC Transplant Consortium.基于美国多中心 HCC 移植协作组的研究：建立并验证肝移植术后肝细胞癌患者复发模型（RELAPSE）
Liver Transpl. 2023 Jul 1;29(7):683-697. doi: 10.1097/LVT.0000000000000145. Epub 2023 Apr 10.
5
Preoperative assessment of microvascular invasion risk using gadoxetate-enhanced MRI for predicting outcomes after liver transplantation for single hepatocellular carcinoma within the Milan criteria.使用钆塞酸增强 MRI 对米兰标准内单个肝细胞癌进行术前微血管侵犯风险评估，以预测肝移植术后的结局。
Eur Radiol. 2024 Jan;34(1):498-508. doi: 10.1007/s00330-023-09936-y. Epub 2023 Jul 28.
6
Assessing Competing Risks for Death Following Liver Transplantation for Hepatocellular Carcinoma.评估肝癌患者肝移植术后死亡的竞争风险。
Dig Dis Sci. 2019 Apr;64(4):1001-1007. doi: 10.1007/s10620-019-05538-1.
7
Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.同型半胱氨酸：甲胎蛋白阴性肝细胞癌肝移植的新型预后生物标志物。
Cancer Biomark. 2020;29(2):197-206. doi: 10.3233/CBM-201545.
8
Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era.在 MELD 时代肝移植后肝细胞癌复发的发生率和危险因素。
Dig Dis Sci. 2012 Mar;57(3):806-12. doi: 10.1007/s10620-011-1910-9. Epub 2011 Sep 28.
9
Prediction of hepatocellular carcinoma recurrence after liver transplantation: Comparison of four explant-based prognostic models.肝移植后肝细胞癌复发的预测：四种基于肝外植体的预后模型比较
Liver Int. 2017 May;37(5):717-726. doi: 10.1111/liv.13388. Epub 2017 Mar 24.
10
Advantage of early liver transplantation whenever indicated for hepatocellular carcinoma recurrence after primary liver resection.对于原发性肝癌切除术后肝癌复发，只要有指征，早期肝移植的优势。
Biomed J. 2019 Oct;42(5):335-342. doi: 10.1016/j.bj.2019.04.001. Epub 2019 Oct 29.
引用本文的文献
1
Challenges related to clinical decision-making in hepatocellular carcinoma recurrence post-liver transplantation: Is there a hope?肝移植后肝细胞癌复发的临床决策相关挑战：有希望吗？
World J Transplant. 2024 Sep 18;14(3):96637. doi: 10.5500/wjt.v14.i3.96637.
本文引用的文献
1
Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review.肝癌肝移植术后复发的预测模型：全面综述。
Clin Mol Hepatol. 2022 Oct;28(4):739-753. doi: 10.3350/cmh.2022.0060. Epub 2022 Apr 26.
2
Clinical and Molecular-Based Approach in the Evaluation of Hepatocellular Carcinoma Recurrence after Radical Liver Resection.根治性肝切除术后肝细胞癌复发评估中的临床及基于分子的方法
Cancers (Basel). 2021 Jan 29;13(3):518. doi: 10.3390/cancers13030518.
3
Construction of a disease-specific lncRNA-miRNA-mRNA regulatory network reveals potential regulatory axes and prognostic biomarkers for hepatocellular carcinoma.构建疾病特异性 lncRNA-miRNA-mRNA 调控网络揭示肝癌潜在的调控轴和预后生物标志物。
Cancer Med. 2020 Dec;9(24):9219-9235. doi: 10.1002/cam4.3526. Epub 2020 Nov 24.
4
Analysis of preoperative circulating tumor cells for recurrence in patients with hepatocellular carcinoma after liver transplantation.肝移植术后肝细胞癌患者术前循环肿瘤细胞与复发的分析
Ann Transl Med. 2020 Sep;8(17):1067. doi: 10.21037/atm-20-2751.
5
Role of Allelic Imbalance in Predicting Hepatocellular Carcinoma (HCC) Recurrence Risk After Liver Transplant.等位基因不平衡在预测肝移植后肝细胞癌（HCC）复发风险中的作用
Ann Transplant. 2019 Apr 24;24:223-233. doi: 10.12659/AOT.913692.
6
Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival.晚期 HCC 的随机试验和终点：PFS 作为生存替代指标的作用。
J Hepatol. 2019 Jun;70(6):1262-1277. doi: 10.1016/j.jhep.2019.01.028. Epub 2019 Mar 31.
7
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.估算 2018 年全球癌症发病率和死亡率：GLOBOCAN 来源和方法。
Int J Cancer. 2019 Apr 15;144(8):1941-1953. doi: 10.1002/ijc.31937. Epub 2018 Dec 6.
8
Molecular Scoring of Hepatocellular Carcinoma for Predicting Metastatic Recurrence and Requirements of Systemic Chemotherapy.肝细胞癌预测转移复发及全身化疗需求的分子评分
Cancers (Basel). 2018 Sep 29;10(10):367. doi: 10.3390/cancers10100367.
9
Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA.液体活检在肝细胞癌中作为预后和预测生物标志物的临床应用：循环肿瘤细胞和循环肿瘤 DNA。
J Exp Clin Cancer Res. 2018 Sep 3;37(1):213. doi: 10.1186/s13046-018-0893-1.
Zotero 插件